MARKET

RTGN

RTGN

RETINALGENIX TECHNOLOGIES INC
OTCPK
4.000
NaN%
Opening 09:30 05/22 EDT
OPEN
--
PREV CLOSE
4.000
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
4.010
52 WEEK LOW
3.200
MARKET CAP
75.37M
P/E (TTM)
-30.5810
1D
5D
1M
3M
1Y
5Y
1D
RetinalGenix net loss widens 1% to $590,489 in Q1 FY26
PUBT · 1d ago
RetinalGenix delays quarterly report filing, needs more time to finalize financial statements
PUBT · 05/15 13:53
Based on the provided financial report articles, I generated the title for the article: **"Sanovas, Inc. (RTGN) Financial Report for Fiscal Year 2025 and 2024"** Please note that the title may not be exact, as the provided text appears to be a financial report with various sections and data, and the title may not be explicitly stated.
Press release · 04/16 07:11
RetinalGenix FY25 net loss narrows 44% to $2,428,595
PUBT · 04/15 10:11
RetinalGenix delays filing annual report, seeks extra time to finalize financials
Reuters · 03/30 10:04
RetinalGenix CFO Michael Cory Zwerling resigns effective immediately
Reuters · 03/26 20:50
RetinalGenix Reveals AI Retinal Mapping Links Eye Changes to Neurodegenerative and Metabolic Diseases
Reuters · 01/14 11:01
RetinalGenix Reports on its Science and Mission in Light of New AI-Driven Retinal Mapping Study
Barchart · 01/14 05:01
More
About RTGN
RetinalGenix Technologies Inc. is an ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas. The Company's proprietary High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular and metabolic systems, as well as diabetic conditions, Alzheimer’s disease and Parkinson’s disease. Its RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians available 24/7. It is also engaged in the development of its product candidates: RTG-2023 and RTG-2024. RTG-2023 for the treatment of dry age-related macular degeneration (dry AMD). RTG-2024 for the treatment of Alzheimer’s syndrome dementia.

Webull offers RetinalGenix Technologies Inc stock information, including OTCPK: RTGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RTGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RTGN stock methods without spending real money on the virtual paper trading platform.